Medication rule of traditional Chinese medicine in the treatment of hypertensive early renal damage
CHEN Kaili1 ZHANG Danhua1 XU Peicong1 WANG Baolin1 DENG Wei2#br#
1.The First Clinical Medical College, Henan University of Chinese Medicine, Henan Province, Zhengzhou 450000, China;
2.Department of Geriatrics, the First Affiliated Hospital of Henan University of Chinese Medicine, Henan Province, Zhengzhou 450000, China
Abstract:Objective To study the medication rule of traditional Chinese medicine in the treatment of hypertensive early renal damage. Methods A database was established by collecting hypertensive early renal damage related journal articles recorded on CNKI, VIP and Wanfang database from inception to December 2021, and the frequency, nature and flavour and channel tropism, association rules, complex network visualization, system cluster analysis were conducted for the Chinese medicines that met the standards. Results Among the 69 Chinese herbal compounds that met the standard. It involved 140 Chinese medicines. Astragali Radix, Salviae Miltiorrhizae Radix Et Rhizoma, Cornifructus, Poria, Dioscoreae Rhizoma were the most used, the four nature of drugs were mainly flat, the five tastes were mostly sweet, bitter and spicy, and the channel tropism were mainly liver, spleen and kidney channels. In the results of association rules, there were seven binomial associations and seven three-term associations. The systematic clustering results were classified into four categories. Conclusion Traditional Chinese medicine in the treatment of hypertensive early renal damage mainly focuses on tonifying and replenishing liver and kidney, invigorating qi and strengthening spleen, calming the liver to stop the wind, draining turbidity and removing blood stasis, and treating both manifestation and root cause of disease.
陈凯丽1 张单华1 徐培聪1 王报林1 邓伟2. 中医药治疗高血压早期肾损害的用药规律[J]. 中国医药导报, 2022, 19(22): 118-122.
CHEN Kaili1 ZHANG Danhua1 XU Peicong1 WANG Baolin1 DENG Wei2. Medication rule of traditional Chinese medicine in the treatment of hypertensive early renal damage. 中国医药导报, 2022, 19(22): 118-122.